This study compares adherence to breast and ovarian cancer screening recommendations among a population cohort of women at familial risk of breast and/or ovarian cancer. This cross-sectional study included 1039 firstdegree female relatives without breast cancer identified from the Ontario site of the Breast Cancer Family Registry. We compared breast and ovarian cancer screening behaviors, using a telephone-administered questionnaire among three groups of women defined by their familial risk (high, moderate, and low) of breast and/or ovarian cancer. Associations between screening behaviors and familial risk were assessed using multinomial regression models adjusted by familial clustering. Women, 40-49 years of age, at moderate or high familial risk were significantly more likely to have had a screening mammogram within the past 12 months [odds ratio (OR): 2.80; 95% confidence interval (CI): 1.40-5.58], and women of less than 50 years of age were more likely to have a clinical breast examination (OR: 1.84; 95% CI: 1.02-3.31) compared with women at low familial risk. Compared with women at low or moderate familial risk, women at high familial risk were significantly more likely to have ever had a genetic test for the BRCA 1/ 2 genes (OR: 2.67; 95% CI: 1.76-4.05). Although the overall level of adherence among high-risk women is suboptimal in the community, women at a higher familial risk are adhering more often to cancer screening recommendations than women at a lower familial risk.
Introduction
Breast cancer is the most common malignancy among Ontario women with an estimated 8700 new diagnoses and 2100 deaths in 2009 (Canadian Cancer Society, 2009) . Women with at least one affected first-degree relative are about twice as likely to develop breast cancer compared with women who have no affected relatives and risks are higher when more than one first-degree relative is affected or when the relative is younger at diagnosis (Pharoah et al., 1997; Collaborative Group on Hormonal Factors in Breast Cancer, 2001) . Furthermore, a woman with a first-degree relative diagnosed with ovarian cancer is twice as likely to develop breast cancer and women with a first-degree relative affected with breast cancer have over two times the risk of developing ovarian cancer compared with women with no affected relatives (Ziogas et al., 2000) .
There is evidence that a significant reduction in the breast cancer mortality can be achieved through mammography screening (Kerlikowske et al., 1995; Humphrey et al., 2002; Nelson et al., 2009) . The Canadian Task Force on the Periodic Health Examination recommends screening for breast cancer by mammography and clinical breast examination (CBE) every 1-2 years for all women aged 50-69 years (Ringash, 2001) . Women with a moderate or high risk of familial breast cancer, determined by the number of first-degree or second-degree relatives with breast cancer and the age of those diagnoses, are recommended to undergo annual mammographic screening examinations starting at the age of 40 years (Warner et al., 1999) . In addition, these moderate and high familial risk women should receive annual CBE starting at the age of 40 years, and those younger than 40 years should receive a CBE with each routine health examination. Only women at high familial risk are recommended for referral to familial cancer clinics for genetic testing. In Ontario, these examinations are freely available within the universal, publicly funded healthcare system.
In women of less than 50 years, higher breast density and biologically more aggressive cancers may reduce the benefit of mammographic screening (Berg et al., 2008) . Ultrasound is more sensitive than mammography for screening women with dense breasts, and it may be particularly useful for the surveillance of young women at high risk (Kolb et al., 2002; Warner et al., 2004) . Women with a BRCA1 or BRCA2 mutation and women who have not undergone testing, but are part of families suggestive of hereditary breast and/or ovarian cancer, are recommended to have transvaginal ultrasounds and evaluation of cancer antigen-125 blood levels every 6-12 months beginning at the age of 25-35 years for ovarian cancer screening (Burke et al., 1997) .
Although the impact of breast screening on breast cancer mortality for women with a family history currently remains unknown, cancer detection rates, an interim indicator of screening effectiveness, have been shown to be greater in women with a family history compared with women without a family history (Kerlikowske et al., 1993; Kerlikowske et al., 2000; Halapy et al., 2004) . Therefore, current breast screening recommendations for high-risk women are based on these findings and on expert opinion (Warner et al., 1999) . Similarly, there is no clear evidence showing the effectiveness of ovarian cancer screening in women at high familial risk and recommendations are based on expert opinion (Evans et al., 2009) .
Previous research has demonstrated that women with a first-degree relative who has been diagnosed with breast cancer are more likely to start screening at an earlier age when compared with women without a family history (Lux et al., 2005) . However, few studies have evaluated adherence to breast and ovarian cancer screening guidelines and recommendations among women at familial risk. The majority of these studies examined women visiting genetic counseling clinics or women from BRCA1/2 mutation families, and show relatively high adherence (67-90%) to CBE and mammography screening recommendations (Lerman et al., 2000; Meiser et al., 2000; Isaacs et al., 2002; Tinley et al., 2004; Antill et al., 2006) and low (10-20%) to high (> 70%) adherence for ovarian cancer screening recommendations (Lerman et al., 2000; Isaacs et al., 2002; Antill et al., 2006) . The high-risk women in these studies may not be representative of women at familial risk in the general population with respect to their cancer screening behaviors. One study that has examined mammography in a population-based group of women found lower adherence, with approximately 40% of women at familial risk receiving a mammogram in the last 11 months (Madlensky et al., 2005) . Another recent population study of women from multiple case breast cancer families showed high adherence to mammography guidelines (74%), but relatively lower adherence to CBE guidelines (45%; Price et al., 2010) . The purpose of this study was to compare adherence with breast and ovarian cancer screening recommendations by level of familial risk among a population cohort of Ontario women, 20-71 years of age, who had at least one first-degree relative diagnosed with breast or ovarian cancer.
Methods

Study population
This study identified a cohort of female relatives of incident cases of invasive breast cancer from the Ontario site of the Breast Cancer Family Registry (BCFR) funded by the US National Cancer Institute. The details of the BCFR and the Ontario site of the BCFR have been previously described (Knight et al., 2002; John et al., 2004) . In brief, cases of invasive breast cancer (probands), pathologically confirmed and diagnosed between 1996 and 1998, were identified from the Ontario Cancer Registry. Physicians were contacted to obtain permission to mail their patients a cancer Family History Questionnaire. Respondents meeting a defined set of family history criteria, and a random sample (25%) of those not meeting the criteria were asked to participate in the Ontario site of the BCFR. Of those eligible at this stage (N = 2587), 1851 (72%) probands participated.
These probands were asked for address information and permission to contact specific living relatives (first degree, those affected with breast, ovarian, or certain other cancers, and their first-degree relatives). An invitation letter to participate in the Ontario site of the BCFR was sent to relatives, and those who agreed to participate were mailed an Epidemiology Questionnaire (EQ) between 1998 and 2004. Our study was conducted a few years after the initial recruitment of relatives. In this study, we identified all female relatives enrolled in the Ontario site of the BCFR who had completed the EQ, were still alive and unaffected by breast cancer at the time of the diagnosis of the proband, and were residents of Ontario. From the 3374 participating female relatives, we identified 2066 (61%) who were residents of Ontario and of these, 1885 (91%) met the other study criteria.
Of the 1885 female relatives identified, 1514 women were between 20 and 69 years of age as of 1 January 2006 and were mailed a Personal History and Screening Questionnaire (PHSQ) between November 2005 and March 2007. Of the women who were sent a questionnaire, 37 were ineligible (deceased, moved out of Ontario, or had acquired dementia) and 177 could not be contacted. Of the 1300 eligible women contacted, 1108 (85.2%) consented to be interviewed. Further exclusions included 37 women who had a breast cancer diagnosis and 32 women who did not have a first-degree relative with breast and/or ovarian cancer. Thus, the final study cohort consisted of 1039 women. This study was approved by Mount Sinai Hospital and University Health Network Research Ethics Boards.
Data collection
The women in this study were initially contacted by a mailed questionnaire during the recruitment of female relatives from the Ontario site of the BCFR between 1998 and 2004. As several years had elapsed since the initial recruitment, a follow-up telephone questionnaire Screening adherence among high-risk women Campitelli et al. 493 (PHSQ) was administered to update changes in health behaviors and key demographic characteristics and to collect detailed information on breast and ovarian cancer screening examinations that were not collected on the EQ.
The age at the interview was calculated as the difference in years between the date of birth and the date of the PHSQ interview. Descriptive analyses used age categories of less than 40, 40-49, 50-59, and more than or equal to 60 years, but regression models were adjusted using age as a continuous variable. Marital status (currently married/ common law, not currently married/common law), the highest level of education attained (high school or less, some college, university, technical or vocational school, and bachelor's degree or higher), the average annual frequency of visiting a healthcare professional in the past 2 years (once a year or less, 2-3 times a year, and 4 or more times a year), hormone therapy use in women of more than 50 years of age (current, former, never), and oral contraceptive use for women aged less than 50 years (former, current, never) were determined using responses to the PHSQ. Finally, body mass index (< 25, 25 to < 30, and Z 30) of the participants in kg/m 2 was derived from information on height (EQ) and weight (PHSQ).
The PHSQ asked women to give either the dates (month and year) of their last mammogram and CBE or their age at the time of last examination. In addition, women were asked whether their breast examinations were for screening purposes (part of a regular check-up or due to a family history of breast cancer) or for nonscreening purposes (examination due to a breast problem/symptom, followup of a previous breast problem, or participation in a research study). The time since last breast examination and the reason for examination were combined into a single variable to characterize a participant's breast screening behavior. Similar methods were used to characterize ovarian cancer screening behaviors [transvaginal ultrasound (TVUS) or cancer antigen 125 (CA-125) blood test]. The study participants were also asked how frequently they conducted breast self-examinations (BSE), whether they had ever had a breast ultrasound for either screening or nonscreening purposes, and whether they ever had a genetic test for the breast and ovarian cancer (BRCA1/2) susceptible genes. The classification of family history of breast and/or ovarian cancer was based on information collected from the Family History Questionnaire completed by the relative's proband using a modified definition of previously referenced groups for familial breast cancer risk (Eccles et al., 2000; Cortesi et al., 2006) . Table 1 shows the criteria for classifying women to low, moderate, or high familial risk of breast and/or ovarian cancer.
Statistical analyses
Pearson w 2 tests assessed the association between familial risk (high vs. low, moderate vs. low, and high vs. moderate) and each characteristic. Primary outcomes included screening for breast or ovarian cancer according to the time since the last screen. For breast cancer screening examinations (mammography, CBE, BSE, breast ultrasound), women with moderate and high familial risks were compared with women at low familial risk (referent). For mammographic screening, we stratified women by age (< 40, 40-49, and Z 50 years) according to current recommendations. In addition, stratified analyses by age (< 50 and Z 50 years) were conducted for the other breast screening examinations. For ovarian cancer screening examinations (TVUS and CA-125 blood test) and genetic testing for the BRCA1/2 genes, women at high familial risk were compared with women at moderate and low familial risk (referent).
Screening outcomes were analyzed using multinomial regression models (Agresti, 2002) . The comparison group was either 'never had a screening test' or 'had a nonscreening examination' except for the analysis of BSE, in which the comparison group was 'once a year or less frequently'. As many study participants were related and might share common cancer screening behaviors, a robust variance estimate was used to adjust for potential correlation due to family clustering (Binder, 1981; Morel, 1989) . All statistical analyses were conducted using SAS version 9.1 (SAS Institute Inc., 2004), and significance was evaluated using two-sided P values at the 5% level.
Results
The study participants included 1039 women from 647 unique families, of which 398 (61.5%) had one family member, 160 (24.7%) had two family members, and 89 (13.8%) had three to eight family members. Using our familial risk definition, 521 (50.1%) women had a low familial risk, 244 (23.5%) had a moderate familial risk, and 274 (26.4%) had a high familial risk. Women at moderate and high familial risk were more likely to be older than women at low familial risk and more likely to have less High Two or more first-degree relatives with breast and/or ovarian cancer diagnosed at any age One or more first-degree relative(s) with both breast and ovarian cancer diagnosed at any age One or more first-degree relative(s) diagnosed with bilateral breast cancer at any age A personal history of ovarian cancer Moderate A self-reported Ashkenazi Jewish background One first-degree relative with breast cancer diagnosed before the age of 40 years One first-degree relative with ovarian cancer One first-degree relative with breast cancer diagnosed after the age of 40 years and two or more second-degree relatives with breast cancer Low
One first-degree relative diagnosed with breast cancer after the age of 40 years education ( Table 2 ). In addition, women at high familial risk were more likely to visit health professionals yearly compared with women at moderate risk.
For women, aged 40-49 years, at moderate or high familial risk, 56.8% had a mammogram within the last 12 months (Table 3) . Compared with women at low familial risk, these women were statistically significantly more likely to have had a screening mammogram [odds ratio (OR): 2.80; 95% confidence interval (CI): 1.40-5.58]. No significant difference in annual mammography was observed in women younger than 40 years of age or 50 years of age or older.
For women of less than the age of 50 years, at moderate or high familial risk, 58.5% had a CBE within the last 12 months (Table 4 ). In addition, 39.3% of these women practiced BSE once a month or more and 13.4% had a screening breast ultrasound. Compared with women at low familial risk, women less than 50 years of age who were at moderate or high familial risk were statistically significantly more likely to have had a screening CBE (OR: 1.84; 95% CI: 1.02-3.31) within the last 12 months or had a screening breast ultrasound (OR: 1.89; 95% CI: 1.03-3.48). There were no significant differences in these breast screening examinations for women 50 years of age or older. The frequency of BSE was also not associated with familial breast cancer risk.
Of the women at high familial risk, 2.8% had received a transvaginal ultrasound and 3.3% had a CA-125 blood test in the last 12 months (Table 5) . Compared with women at low or moderate familial risk, women at high familial risk were statistically significantly more likely to have a screening transvaginal ultrasound (OR: 3.30; 95% CI: 1.60-6.82) or a CA-125 blood test (OR: 4.01; 95% CI: 1.29-12.43) more than 12 months ago. Women at high familial risk were also more likely to have a screening transvaginal ultrasound or a CA-125 blood test within 12 months, although associations were not significant. Women at high familial risk were statistically significantly more likely to have ever had a genetic test for the BRCA 1/2 genes (OR: 2.67; 95% CI: 1.76-4.05) compared with women at low or moderate familial risk.
Discussion
Overall, this study revealed that adherence to breast and ovarian cancer screening was low among a population cohort of first-degree female relatives. However, screening adherence was significantly higher among Ontario women who were recommended for early and more frequent screening based on their age and level of familial risk. Women of less than 50 years of age at moderate and high familial risk for breast cancer reported greater utilization of breast cancer screening compared with women at low familial risk, and women of all ages at high familial risk reported greater utilization of ovarian cancer screening and genetic testing for the BRCA genes when compared with women at low or moderate familial risk.
Previous studies have typically found mammography utilization to be one and a half to three times greater among women with a first-degree relative diagnosed with breast cancer compared with women without a family history of breast cancer (McCaul et al., 1996; Murabito et al., 2001; Shah et al., 2007; Tracy et al., 2008) . Our study showed a near three-fold increase for annual mammography among women of 40-49 years of age at moderate or high familial risk compared with women at low familial risk. Adherence to breast screening examinations may have been greater in women with higher familial risk, given they would have been more likely to receive physician recommendations to undergo screening. Two recent studies have found that a physician or health professional's recommendations were significantly associated with breast cancer screening adherence among women from BRCA1/2 families or multiple case breast cancer families (Tinley et al., 2004; Price et al., 2010) . In addition, a recent meta-analysis reported that women with a family history of breast cancer were significantly more likely to perceive their risk of developing breast cancer as higher than other women and found a positive association between higher perceived risk and mammography screening (Katapodi et al., 2004) . A recent study of this cohort also found a positive association between higher perceived risk and mammography screening (Zhang et al., 2010) .
The overall level of mammography adherence was lower in our study for women at moderate or high familial risk when compared with previous studies. Approximately 57% of women 40-49 years of age at moderate or high familial risk adhered to mammography recommendations. Other studies reported higher levels of mammography adherence ( > 70%) among high risk women less than 50 years of age (Meiser et al., 2000; Isaacs et al., 2002) . However, these previous studies included women visiting clinics for genetic counseling and may have differed from ours that included women in the general population at familial risk. Mammography adherence in our study for all women at moderate or high familial risk (56%) was higher than the 40% reported by one population-based study, but lower than the 74% reported by another populationbased study for women at similar familial risk (Madlensky et al., 2005; Price et al., 2010) .
Similar to mammography, annual CBE was significantly higher in women of less than 50 years of age at moderate or high familial risk compared with women at low familial risk, although there was only a near two-fold increase. In addition, the overall level of adherence to CBE recommendations among women of less than the age of 50 years (59%) was lower than that seen in previous studies among high-risk women of less than 50 years (>85%) (Meiser et al., 2000; Isaacs et al., 2002) . As with mammography adherence, this difference in CBE adherence may be the result of previous studies including women from genetic counseling clinics and not the general population.
In our study, adherence to mammography (65%) and CBE (65%) recommendations was found to be higher in women at moderate or high familial risk over the age of 50 years. However, these breast screening examinations did not differ by familial risk. Although all women of more than 50 years are recommended to have regular mammograms and CBE regardless of their level of familial risk (Ringash 2001) , it was expected that older women at moderate or high familial risk would have been screened more often within the last 12 months. One explanation may be that physicians are recommending yearly breast screening for all women over the age of 50 years with a first-degree relative with breast and/or ovarian cancer, even if their level of familial risk is low. In addition, the frequency of performing BSEs did not vary by familial risk or by age group in our study. This finding may be due to the release of BSE recommendations by the Canadian Task Force on Preventive Health Care in 2001, which reported that regular BSE conferred no benefit in terms of survival from breast cancer (Baxter 2001) .
In our study, women of less than 50 years of age at moderate and high familial risk were more likely to have had a screening breast ultrasound compared with women at low risk (13 vs. 7%), but this association was not found for women more than the age of 50 years. Our observed Excludes women who stated that they had a bilateral mastectomy (N = 6). c Excludes women for whom the reason for mammogram could not be ascertained (N = 24). d P < 0.01. association between breast ultrasound and familial risk only in women younger than 50 years was expected as breast ultrasounds are generally recommended for younger women with denser breast tissue (Kolb et al., 2002) . To our knowledge, there have been no population studies that have evaluated the uptake of breast ultrasound in women at familial risk of breast cancer.
A population-based study of women with at least one first-degree relative with ovarian cancer found that the likelihood of receiving a CA-125 test increased 2.6 times for each affected first-degree relative (Schwartz et al., 1995) . A similar increase in ovarian cancer screening was observed in our study for women at high familial risk compared with low or moderate familial risk. Similar to breast cancer screening examinations, women at high familial risk may be more likely to have ovarian screening examinations compared with women at low or moderate familial risk due to their an increased perceived risk or an increased likelihood to receive recommendations by their physicians to undergo these screening tests. However, there is much less literature studying these factors for ovarian cancer screening adherence compared with mammography adherence. In our study, only 2.8 and 3.3% of high familial risk women received a TVUS or CA-125 blood test within the past 12 months, respectively, although 8-10% of these women had ever received one of these examinations. This level of adherence is lower than previous studies, in which adherence to ovarian screening examinations was approximately 10-20% in the past year (Lerman et al., 2000; Isaacs et al., 2002) and much lower than the 70% adherence level observed in a recent study (Antill et al., 2006) . Adherence to these examinations may be low due to our study analyzing a population cohort of women instead of women referred to genetic counseling clinics or women from BRCA families. Women at high familial risk were also much more likely to have ever had a genetic test for the BRCA genes. Our results concur with a previous study on women from BRCA mutation families that found that the odds of receiving a genetic test for the BRCA1/2 genes significantly increases by 1.6 for every first-degree relative affected with breast cancer (Lerman et al., 1996) . Two studies reported the uptake of BRCA mutation testing to be approximately 50% for unaffected women with a firstdegree relative with a BRCA mutation (Julian-Reynier et al., 2000; Meijers-Heijboer et al., 2000) . In our study, 25.7% of women at high familial risk had ever received a genetic test for the BRCA genes. The difference in uptake rates found in our study compared with other studies in the literature is most likely due to the differences in the study populations.
This study is unique in a way that it compares cancer screening behaviors in women with at least one firstdegree relative diagnosed with breast cancer at differing risks of familial breast cancer. In addition, our study had a much larger sample than similar studies and participants were identified from a population-based cohort instead of from BRCA mutation families or women attending genetic counseling clinics (Lerman et al., 2000; Meiser et al., 2000; Isaacs et al., 2002; Tinley et al., 2004; Antill et al., 2006) .
Despite the strengths of our study, there were a few limitations. First, the study was cross-sectional in design and therefore could not establish a temporal relationship between familial breast cancer risk and cancer screening behaviors. Second, the data on family history of breast cancer were self-reported by the probands. However, studies have shown that patient-reported family cancer histories for first-degree relatives are accurate for breast cancer risk assessments, although accuracy is somewhat lower for second-degree relatives (Murff et al., 2004) . Third, misclassification may have also occurred through the use of self-reported data to measure cancer screening behaviors. Although self-reported mammography data have been found to be accurate for determining whether a woman has had a mammogram, self-reported data are less accurate in determining the time since the last mammogram (Yang et al., 1998) and women tend to underestimate the time since their last mammogram resulting in an overestimation of recent mammography use (Degnan et al., 1992; Gordon et al., 1993) . To estimate the magnitude of recall bias, self-reported date of the last mammogram was validated against the woman's mammography report. Approximately 92% of women self-reported the date of their last mammogram to within 12 months of the actual date abstracted from the report. Fourth, we did not compare utilization of breast magnetic resonance imaging examinations among familial risk groups due to the small number of women in the cohort (approximately 1%) who had these tests for screening purposes. Finally, the generalizability of our results to other populations may be limited by differences in cancer screening recommendations and healthcare systems between jurisdictions.
The results of this study demonstrate that adherence to screening recommendations among a population cohort of Ontario women with at least one first-degree relative with breast and/or ovarian cancer is suboptimal. We speculate that high-risk women in the general population are less likely to be referred appropriately for screening surveillance compared with those who have visited familial genetic counseling clinics. Although overall adherence was observed to be lower, women at a higher familial risk are Odds ratio compares women at high familial risk with women at moderate or low familial risk. Models adjusted for age at interview, education, and number of health professional visits. c Excludes women who stated that they had a bilateral oophorectomy (N = 82). d P < 0.001. e P < 0.05.
adhering more often to breast and ovarian cancer screening recommendations than women at a lower familial risk.
